Influence of Bevacizumab and VEGF on Platelet Aggregation
N/A
N/A
Both
Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Trial Information
Influence of Bevacizumab and VEGF on Platelet Aggregation
OBJECTIVES:
- To determine the influence of bevacizumab on platelet aggregation in patients receiving
bevacizumab for cancer.
- To determine the influence of VEGF on platelet aggregation.
- To determine the influence of VEGF or bevacizumab on cyclooxygenesis.
- To determine if the sequence of medication plays a role in platelet aggregation.
OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are
analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial
activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble
P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Receiving bevacizumab for cancer
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Influence of bevacizumab on platelet aggregation
Safety Issue:
No
Principal Investigator
Roger von Moos, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Kantonsspital Graubuenden
Authority:
Unspecified
Study ID:
CDR0000631252
NCT ID:
NCT00898794
Start Date:
October 2007
Completion Date:
Related Keywords:
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific
- unspecified adult solid tumor, protocol specific
- unspecified childhood solid tumor, protocol specific
- Neoplasms
Name | Location |
|---|
